NasdaqCM - Delayed Quote USD

SeaStar Medical Holding Corporation (ICUCW)

0.0106 0.0000 (0.00%)

At close: November 3 at 11:53:40 AM EST

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

GlobeNewswire 2d ago

ICU
FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

GlobeNewswire 3d ago

ICU
ICU: QUELIMMUNE® Demonstrates Statistically Significant Survival Benefit in SAVE Registry Patients

Zacks Small Cap Research 14d ago

ICU
SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI

GlobeNewswire 15d ago

ICU
SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

GlobeNewswire 23d ago

ICU
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

GlobeNewswire 30d ago

ICU
SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

GlobeNewswire 1mo ago

ICU
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

GlobeNewswire 1mo ago

ICU
New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

GlobeNewswire 1mo ago

ICU
SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

GlobeNewswire 1mo ago

ICU
SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

GlobeNewswire 1mo ago

ICU
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

GlobeNewswire 1mo ago

ICU

U.S. markets closed

SeaStar Medical Holding Corporation (ICUCW)

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

ICU: QUELIMMUNE® Demonstrates Statistically Significant Survival Benefit in SAVE Registry Patients

SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference